These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 32607773)

  • 1. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.
    Ferrante ND; Lo Re V
    Curr HIV/AIDS Rep; 2020 Aug; 17(4):405-414. PubMed ID: 32607773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis D: A Review.
    Negro F; Lok AS
    JAMA; 2023 Dec; 330(24):2376-2387. PubMed ID: 37943548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBV/HDV Coinfection: A Challenge for Therapeutics.
    Koh C; Da BL; Glenn JS
    Clin Liver Dis; 2019 Aug; 23(3):557-572. PubMed ID: 31266627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of delta hepatitis.
    Gunsar F
    Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of delta virus infection on the virologic status in Egyptian patients with chronic hepatitis B virus genotype D.
    Fouad R; Abdo M; Eldeen HG; Sabry D; Atef M; Ahmed R; Zayed N
    J Med Virol; 2016 May; 88(5):837-42. PubMed ID: 26488214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.
    Bockmann JH; Grube M; Hamed V; von Felden J; Landahl J; Wehmeyer M; Giersch K; Hall MT; Murray JM; Dandri M; Lüth S; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    BMC Gastroenterol; 2020 Jan; 20(1):24. PubMed ID: 32000689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice.
    Duehren S; Uchida T; Tsuge M; Hiraga N; Uprichard SL; Etzion O; Glenn J; Koh C; Heller T; Cotler SJ; Oka S; Chayama K; Dahari H
    Virus Res; 2024 Nov; 349():199451. PubMed ID: 39168375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-F HBV/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon.
    Melo Da Silva E; Kay A; Lobato C; Muwonge R; Zoulim F; Brites C; Parana R; Trepo C
    J Med Virol; 2019 Jun; 91(6):1081-1086. PubMed ID: 30695106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
    Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B-coinfected adults in care in the United States.
    Ferrante ND; Kallan MJ; Sukkestad S; Kodani M; Kitahata MM; Cachay ER; Bhattacharya D; Heath S; Napravnik S; Moore RD; Yendewa G; Mayer KH; Reddy KR; Hayden T; Kamili S; Martin JN; Kim HN; Lo Re V
    J Viral Hepat; 2023 Nov; 30(11):879-888. PubMed ID: 37488783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis delta and HIV infection.
    Soriano V; Sherman KE; Barreiro P
    AIDS; 2017 Apr; 31(7):875-884. PubMed ID: 28121714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California.
    Gish RG; Yi DH; Kane S; Clark M; Mangahas M; Baqai S; Winters MA; Proudfoot J; Glenn JS
    J Gastroenterol Hepatol; 2013 Sep; 28(9):1521-5. PubMed ID: 23574043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of hepatitis delta virus among patients with chronic hepatitis B virus infection and HIV-1 in an intermediate hepatitis B virus endemic region.
    Saravanan S; Madhavan V; Velu V; Murugavel KG; Waldrop G; Solomon SS; Balakrishnan P; Kumarasamy N; Smith DM; Mayer KH; Solomon S; Thyagarajan SP
    J Int Assoc Provid AIDS Care; 2014; 13(1):85-90. PubMed ID: 23722085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study.
    Sheng WH; Hung CC; Kao JH; Chang SY; Chen MY; Hsieh SM; Chen PJ; Chang SC
    Clin Infect Dis; 2007 Apr; 44(7):988-95. PubMed ID: 17342655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication.
    Goyal A; Murray JM
    Theor Popul Biol; 2016 Dec; 112():60-69. PubMed ID: 27594346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1.
    Spaan M; Carey I; Bruce M; Shang D; Horner M; Dusheiko G; Agarwal K
    J Hepatol; 2020 Jun; 72(6):1097-1104. PubMed ID: 31981726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
    J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.
    Béguelin C; Moradpour D; Sahli R; Suter-Riniker F; Lüthi A; Cavassini M; Günthard HF; Battegay M; Bernasconi E; Schmid P; Calmy A; Braun DL; Furrer H; Rauch A; Wandeler G;
    J Hepatol; 2017 Feb; 66(2):297-303. PubMed ID: 27746337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innate immune recognition and modulation in hepatitis D virus infection.
    Jung S; Altstetter SM; Protzer U
    World J Gastroenterol; 2020 Jun; 26(21):2781-2791. PubMed ID: 32550754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.